{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T01:23:51Z","timestamp":1755998631541},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Zoledronate, a bisphosphonate, is a potent first-line treatment for osteoporosis. It is also a preferred treatment for hypercalcemia especially when unresponsive to intravenous fluids. Bisphosphonates can cause acute phase reactions that mimic opioid withdrawal symptoms, which can confound provider decision-making. Our case highlights cognitive bias involving a patient with opioid use disorder who received zoledronate for hypercalcemia secondary to immobilization and significant bone infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 41-year-old male is admitted with a past medical history of active intravenous opioid use complicated by group A streptococcal bacteremia with L5-S1 discitis and osteomyelitis, L2-L3 osteomyelitis, and left ankle abscess\/septic arthritis status post left ankle washout. His pain was well-controlled by acute pain service with ketamine infusion (discontinued earlier), opioids, acetaminophen, buprenorphine-naloxone, cyclobenzaprine, gabapentin, and naproxen. Intravenous opioids were discontinued, slightly decreasing the opioid regimen. A day later, the patient reported tachycardia, diaphoresis, myalgias, and chills, which the primary team reconsulted acute pain service for opioid withdrawal. However, the patient received a zoledronate infusion for hypercalcemia, on the same day intravenous opioids were discontinued. He had no other medications known to cause withdrawal-like symptoms per chart review. Therefore, it was suspected that an acute phase reaction occurred, commonly seen within a few days of bisphosphonate use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Zoledronate, well known for causing acute phase reactions, was likely the cause of withdrawal-like symptoms. Acute phase reactions with bisphosphonates mostly occur in the first infusion, and the incidence decreases with subsequent infusions. Symptoms typically occur 24\u201372\u00a0h post-infusion, and last at most for 72\u00a0h. Cognitive bias led the primary team to be concerned with opioid withdrawal rather than investigating other causes for the patient\u2019s presentation. Therefore, providers should thoroughly investigate potential etiologies and rule them out accordingly to provide the best care. Health care providers should also be aware of the implicit biases that potentially impact the quality of care they provide to patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-024-00464-8","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T19:01:11Z","timestamp":1714590071000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An acute phase reaction from zoledronate mimicking symptoms seen in opioid withdrawal: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Pankti P.","family":"Acharya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crystal","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"464_CR1","unstructured":"Greear EL, Bankole A. Zoledronate. In: StatPearls. StatPearls Publishing; 2023."},{"issue":"2","key":"464_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.14310\/horm.2002.1226","volume":"8","author":"PD Papapetrou","year":"2009","unstructured":"Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens). 2009;8(2):96\u2013110. https:\/\/doi.org\/10.14310\/horm.2002.1226.","journal-title":"Hormones (Athens)"},{"issue":"1","key":"464_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bone.2011.01.003","volume":"49","author":"M Pazianas","year":"2011","unstructured":"Pazianas M, Abrahamsen B. Safety of bisphosphonates. Bone. 2011;49(1):103\u201310. https:\/\/doi.org\/10.1016\/j.bone.2011.01.003.","journal-title":"Bone"},{"issue":"9","key":"464_CR4","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010;95(9):4380\u20137. https:\/\/doi.org\/10.1210\/jc.2010-0597.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"464_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00198-017-3992-5","volume":"28","author":"AW Popp","year":"2017","unstructured":"Popp AW, Senn R, Curkovic I, et al. Factors associated with acute-phase response of bisphosphonate-na\u00efve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate. Osteoporos Int. 2017;28(6):1995\u20132002. https:\/\/doi.org\/10.1007\/s00198-017-3992-5.","journal-title":"Osteoporos Int"},{"issue":"3","key":"464_CR6","first-page":"175","volume":"15","author":"P Mottaghi","year":"2010","unstructured":"Mottaghi P. Intravenous bisphosphonates for postmenopausal osteoporosis. J Res Med Sci. 2010;15(3):175\u201384.","journal-title":"J Res Med Sci"},{"issue":"5","key":"464_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4158\/EP161638.OR","volume":"24","author":"C Crotti","year":"2018","unstructured":"Crotti C, Watts NB, De Santis M, et al. Acute phase reactions after zoledronic acid infusion: protective role of 25-hydroxyvitamine D and previous oral bisphosphonate therapy. Endocr Pract. 2018;24(5):405\u201310.","journal-title":"Endocr Pract"},{"key":"464_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115390","volume":"137","author":"IR Reid","year":"2020","unstructured":"Reid IR, Green JR, Lyles KW, et al. Zoledronate. Bone. 2020;137: 115390.","journal-title":"Bone"},{"issue":"4","key":"464_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/imj.13030","volume":"46","author":"A Trinh","year":"2016","unstructured":"Trinh A, Wong P, Ebeling PR, Fuller PJ, Milat F. Severe acute phase response after intravenous zoledronic acid in adult patients with cerebral palsy. Intern Med J. 2016;46(4):506\u20137.","journal-title":"Intern Med J"},{"issue":"7","key":"464_CR10","volume":"15","author":"M Jamil","year":"2023","unstructured":"Jamil M, Daneshvar A, Nachawati D, El Sharu H, Meysami A. A rare presentation of zoledronate-induced systemic inflammatory response. Cureus. 2023;15(7): e41524.","journal-title":"Cureus"},{"issue":"3","key":"464_CR11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.bone.2007.05.002","volume":"41","author":"CF Munns","year":"2007","unstructured":"Munns CF, Rajab MH, Hong J, et al. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone. 2007;41(3):366\u201370.","journal-title":"Bone"},{"issue":"1","key":"464_CR12","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1186\/s12889-021-11551-9","volume":"21","author":"LA Keister","year":"2021","unstructured":"Keister LA, Stecher C, Aronson B, McConnell W, Hustedt J, Moody JW. Provider bias in prescribing opioid analgesics: a study of electronic medical records at a Hospital Emergency Department. BMC Public Health. 2021;21(1):1518. https:\/\/doi.org\/10.1186\/s12889-021-11551-9.","journal-title":"BMC Public Health"},{"issue":"11","key":"464_CR13","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1007\/s11606-013-2441-1","volume":"28","author":"EN Chapman","year":"2013","unstructured":"Chapman EN, Kaatz A, Carnes M. Physicians and implicit bias: how doctors may unwittingly perpetuate health care disparities. J Gen Intern Med. 2013;28(11):1504\u201310. https:\/\/doi.org\/10.1007\/s11606-013-2441-1.","journal-title":"J Gen Intern Med"},{"key":"464_CR14","unstructured":"Take a Test. https:\/\/implicit.harvard.edu\/implicit\/takeatest.html. Accessed 20 Feb 2024."},{"issue":"5","key":"464_CR15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1176\/appi.ps.201600056","volume":"68","author":"A Kennedy-Hendricks","year":"2017","unstructured":"Kennedy-Hendricks A, Barry CL, Gollust SE, Ensminger ME, Chisolm MS, McGinty EE. Social stigma toward persons with prescription opioid use disorder: associations with public support for punitive and public health-oriented policies. Psychiatr Serv. 2017;68(5):462\u20139. https:\/\/doi.org\/10.1176\/appi.ps.201600056.","journal-title":"Psychiatr Serv"},{"issue":"5","key":"464_CR16","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.pain.2010.12.005","volume":"152","author":"BB Drwecki","year":"2011","unstructured":"Drwecki BB, Moore CF, Ward SE, Prkachin KM. Pain. 2011;152(5):1001\u20136. https:\/\/doi.org\/10.1016\/j.pain.2010.12.005.","journal-title":"Pain"},{"key":"464_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108486","volume":"131","author":"J Bielenberg","year":"2021","unstructured":"Bielenberg J, Swisher G, Lembke A, Haug NA. A systematic review of stigma interventions for providers who treat patients with substance use disorders. J Subst Abuse Treat. 2021;131: 108486. https:\/\/doi.org\/10.1016\/j.jsat.2021.108486.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"464_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/dar.12619","volume":"37","author":"VR Kostadinov","year":"2018","unstructured":"Kostadinov VR, Roche AM, McEntee A, Allan JM, Meumann NR, McLaughlin LL. Brief workshops to teach drug and alcohol first aid: a pilot evaluation study. Drug Alcohol Rev. 2018;37(1):23\u20137. https:\/\/doi.org\/10.1111\/dar.12619.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"464_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11420-018-9643-3","volume":"15","author":"J Avery","year":"2019","unstructured":"Avery J, Knoepflmacher D, Mauer E, et al. Improvement in residents\u2019 attitudes toward individuals with substance use disorders following an online training module on stigma. HSS J. 2019;15(1):31\u20136. https:\/\/doi.org\/10.1007\/s11420-018-9643-3.","journal-title":"HSS J"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00464-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-024-00464-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00464-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T16:08:40Z","timestamp":1728576520000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-024-00464-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["464"],"URL":"https:\/\/doi.org\/10.1186\/s13722-024-00464-8","relation":{},"ISSN":["1940-0640"],"issn-type":[{"type":"electronic","value":"1940-0640"}],"subject":[],"published":{"date-parts":[[2024,5,1]]},"assertion":[{"value":"25 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}